Literature DB >> 6444713

Zinc deficiency, acrodermatitis enteropathica, optic atrophy, subacute myelo-optic neuropathy, and 5,7-dihalo-8-quinolinols.

F M Sturtevant.   

Abstract

Acrodermatitis enteropathica, a heritable disease of zinc deficiency, was formerly amenable to treatment only with dihaloquinolinol drugs. A few cases of optic atrophy were reported in surviving patients and were proposed as examples of ocular drug toxicity, principally because of the association between iodochlorhydroxyquin and subacute myelo-optic neuropathy (SMON) in Japan. An alternate hypothesis is now offered: that the optic atrophy was secondary to the zinc deficiency, which is consistent with diverse evidence cited from the literature. Therefore, it would seem worthwhile to investigate zinc in cases of disk pallor described as idiopathic or drug associated, and to investigate visual function in cases of severe malnourishment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6444713

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

1.  Clioquinol inhibits dopamine-β-hydroxylase secretion and noradrenaline synthesis by affecting the redox status of ATOX1 and copper transport in human neuroblastoma SH-SY5Y cells.

Authors:  Masato Katsuyama; En Kimura; Masakazu Ibi; Kazumi Iwata; Misaki Matsumoto; Nozomi Asaoka; Chihiro Yabe-Nishimura
Journal:  Arch Toxicol       Date:  2020-10-09       Impact factor: 5.153

2.  Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy.

Authors:  J L Arbiser; S K Kraeft; R van Leeuwen; S J Hurwitz; M Selig; G R Dickersin; A Flint; H R Byers; L B Chen
Journal:  Mol Med       Date:  1998-10       Impact factor: 6.354

3.  Clioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathica.

Authors:  Jim Geiser; Robert C De Lisle; David Finkelstein; Paul A Adlard; Ashley I Bush; Glen K Andrews
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.